Your browser doesn't support javascript.
loading
Sex-Based Analysis of Workflow and Outcomes in Acute Ischemic Stroke Patients Treated With Alteplase Versus Tenecteplase.
Kim, Diana J; Singh, Nishita; Catanese, Luciana; Yu, Amy Y X; Demchuk, Andrew M; Lloret-Villas, Mar I; Deschaintre, Yan; Coutts, Shelagh B; Khosravani, Houman; Appireddy, Ramana; Moreau, Francois; Gubitz, Gord; Tkach, Aleksander; Dowlatshahi, Dar; Medvedev, George; Mandzia, Jennifer; Pikula, Aleksandra; Shankar, Jai; Williams, Heather; Manosalva, Herbert; Siddiqui, Muzaffar; Zafar, Atif; Imoukhuede, Oje; Hunter, Gary; Phillips, Stephen; Hill, Michael D; Poppe, Alexandre Y; Ademola, Ayoola; Shamy, Michel; Bala, Fouzi; Sajobi, Tolulope T; Swartz, Richard H; Almekhlafi, Mohammed A; Menon, Bijoy K; Field, Thalia S.
Afiliação
  • Kim DJ; Department of Clinical Neurosciences, Cumming School of Medicine (D.J.K., A.M.D., S.B.C., M.D.H., A.A., F.B., T.T.S., M.A.A., B.K.M.), University of Calgary, AB, Canada.
  • Singh N; Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada (N.S., J.S.).
  • Catanese L; Hamilton Health Sciences Centre, McMaster University, Hamilton, ON, Canada (L.C.).
  • Yu AYX; Division of Neurology, Sunnybrook Health Sciences Centre (A.Y.X.Y., H.K., R.H.S.), University of Toronto, ON, Canada.
  • Demchuk AM; Department of Clinical Neurosciences, Cumming School of Medicine (D.J.K., A.M.D., S.B.C., M.D.H., A.A., F.B., T.T.S., M.A.A., B.K.M.), University of Calgary, AB, Canada.
  • Lloret-Villas MI; Department of Radiology, Cumming School of Medicine (A.M.D., S.B.C., M.D.H., M.A.A., B.K.M.), University of Calgary, AB, Canada.
  • Deschaintre Y; Department of Community Health Sciences, Cumming School of Medicine (A.M.D., S.B.C., M.D.H., A.A., T.T.S., M.A.A., B.K.M.), University of Calgary, AB, Canada.
  • Coutts SB; Division of Neurology, University of Alberta, Edmonton, Canada (M.I.L.-V.).
  • Khosravani H; Department of Neurosciences, Université de Montréal, QC, Canada (Y.D.).
  • Appireddy R; Department of Clinical Neurosciences, Cumming School of Medicine (D.J.K., A.M.D., S.B.C., M.D.H., A.A., F.B., T.T.S., M.A.A., B.K.M.), University of Calgary, AB, Canada.
  • Moreau F; Department of Radiology, Cumming School of Medicine (A.M.D., S.B.C., M.D.H., M.A.A., B.K.M.), University of Calgary, AB, Canada.
  • Gubitz G; Department of Community Health Sciences, Cumming School of Medicine (A.M.D., S.B.C., M.D.H., A.A., T.T.S., M.A.A., B.K.M.), University of Calgary, AB, Canada.
  • Tkach A; Division of Neurology, Sunnybrook Health Sciences Centre (A.Y.X.Y., H.K., R.H.S.), University of Toronto, ON, Canada.
  • Dowlatshahi D; Division of Neurology, Queen's University, Kingston, ON, Canada (R.A.).
  • Medvedev G; Université de Sherbrooke, QC, Canada (F.M.).
  • Mandzia J; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (G.G., S.P.).
  • Pikula A; Kelowna General Hospital, BC, Canada (A.T.).
  • Shankar J; Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, ON, Canada (D.D., M. Shamy).
  • Williams H; Royal Columbian Hospital, New Westminster, BC, Canada (G.M.).
  • Manosalva H; London Health Sciences Centre, Western University, London, ON, Canada (J.M.).
  • Siddiqui M; Toronto Western Hospital (A.P.), University of Toronto, ON, Canada.
  • Zafar A; Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada (N.S., J.S.).
  • Imoukhuede O; Queen Elizabeth Hospital, Charlottetown, PE, Canada (H.W.).
  • Hunter G; Medicine Hat Regional Hospital, AB, Canada (H.M.).
  • Phillips S; Grey Nuns Community Hospital, Edmonton, AB, Canada (M.S.).
  • Hill MD; St Michael's Hospital, Toronto, ON, Canada (A.Z.).
  • Poppe AY; Red Deer Regional Hospital, AB, Canada (O.I.).
  • Ademola A; University of Saskatchewan, Saskatoon, Canada (G.H.).
  • Shamy M; Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (G.G., S.P.).
  • Bala F; Department of Clinical Neurosciences, Cumming School of Medicine (D.J.K., A.M.D., S.B.C., M.D.H., A.A., F.B., T.T.S., M.A.A., B.K.M.), University of Calgary, AB, Canada.
  • Sajobi TT; Department of Radiology, Cumming School of Medicine (A.M.D., S.B.C., M.D.H., M.A.A., B.K.M.), University of Calgary, AB, Canada.
  • Swartz RH; Department of Community Health Sciences, Cumming School of Medicine (A.M.D., S.B.C., M.D.H., A.A., T.T.S., M.A.A., B.K.M.), University of Calgary, AB, Canada.
  • Almekhlafi MA; Centre Hospitalier de l'Université de Montréal, QC, Canada (A.Y.P.).
  • Menon BK; Department of Clinical Neurosciences, Cumming School of Medicine (D.J.K., A.M.D., S.B.C., M.D.H., A.A., F.B., T.T.S., M.A.A., B.K.M.), University of Calgary, AB, Canada.
  • Field TS; Department of Community Health Sciences, Cumming School of Medicine (A.M.D., S.B.C., M.D.H., A.A., T.T.S., M.A.A., B.K.M.), University of Calgary, AB, Canada.
Stroke ; 55(2): 288-295, 2024 02.
Article em En | MEDLINE | ID: mdl-38174568
ABSTRACT

BACKGROUND:

Understanding sex differences in stroke care is important in reducing potential disparities. Our objective was to explore sex differences in workflow efficiency, treatment efficacy, and safety in the AcT trial (Alteplase Compared to Tenecteplase).

METHODS:

AcT was a multicenter, registry-linked randomized noninferiority trial comparing tenecteplase (0.25 mg/kg) with alteplase (0.9 mg/kg) in acute ischemic stroke within 4.5 hours of onset. In this post hoc analysis, baseline characteristics, workflow times, successful reperfusion (extended Thrombolysis in Cerebral Infarction score ≥2b), symptomatic intracerebral hemorrhage, 90-day functional independence (modified Rankin Scale score, 0-1), and 90-day mortality were compared by sex. Mixed-effects regression analysis was used adjusting for age, stroke severity, and occlusion site for outcomes.

RESULTS:

Of 1577 patients treated with intravenous thrombolysis (2019-2022), 755 (47.9%) were women. Women were older (median, 77 [68-86] years in women versus 70 [59-79] years in men) and had a higher proportion of severe strokes (National Institutes of Health Stroke Scale score >15; 32.4% versus 24.9%) and large vessel occlusions (28.7% versus 21.5%) compared with men. All workflow times were comparable between sexes. Women were less likely to achieve functional independence (31.7% versus 39.8%; unadjusted relative risk, 0.80 [95% CI, 0.70-0.91]) and had higher mortality (17.7% versus 13.3%; unadjusted relative risk, 1.33 [95% CI, 1.06-1.69]). Adjusted analysis showed no difference in outcomes between sexes.

CONCLUSIONS:

Differences in prognostic factors of age, stroke severity, and occlusion site largely accounted for higher functional dependence and mortality in women. No sex disparities were apparent in workflow quality indicators. Given the integration of the AcT trial into clinical practice, these results provide reassurance that no major sex biases are apparent in acute stroke management throughout participating Canadian centers. REGISTRATION URL https//www.clinicaltrials.gov; Unique identifier NCT03889249.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativador de Plasminogênio Tecidual / Tenecteplase / AVC Isquêmico Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Stroke Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativador de Plasminogênio Tecidual / Tenecteplase / AVC Isquêmico Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Stroke Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá